Overview

Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol Craving

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, proof of concept laboratory study to recruit N=70 (35 Males / 35 Females) non-treatment seeking, heavy drinkers with alcohol use disorder (AUD). It is hypothesized that randomization to 1.5mgs dexamethasone versus placebo will decrease alcohol craving during stress by decreasing basal cortisol, increasing anti-inflammatory cytokine levels and potentially normalizing the immune response to stress.
Phase:
Early Phase 1
Details
Lead Sponsor:
Stony Brook University
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate